Novocure Ltd
NASDAQ:NVCR

  • LAST PRICE
    17.9000
  • TODAY'S CHANGE (%)
    -1.0100 (-5.3411%)
  • Bid / Lots
    17.7400/ 1
  • Ask / Lots
    18.1000/ 2
  • Open / Previous Close
    18.8700 / 18.9100
  • Day Range
    17.5100
    19.0700
  • 52 Week Range
    10.8700
    31.7300
  • Volume
    1,130,576

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Medical Equipment, Supplies & Distribution Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
NVCR
Novocure Ltd
1.9B
-11.4x
---
STAA
STAAR Surgical Co
1.9B
113.2x
+31.52%
WRBY
Warby Parker Inc
1.7B
-37.4x
---
RXST
Rxsight Inc
2.1B
-52.4x
---
UFPT
UFP Technologies Inc
2.5B
50.9x
+24.81%
TXG
10X Genomics Inc
2.6B
-10.8x
---
As of 2024-08-18

Company Information

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Contact Information

Headquarters
No. 4 The Forum, Grenville StreetSAINT HELIER, Jersey JE2 4UF
Phone
153-475-6700
Fax
---

Executives

Executive Chairman of the Board
William Doyle
President, Chief Executive Officer, Director
Asaf Danziger
Chief Financial Officer
Ashley Cordova
Chief Operating Officer
Wilhelmus Groenhuysen
Chief Human Resource Officer
Michael Puri

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.9B
Revenue (TTM)
$550.0M
Shares Outstanding
108.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.72
EPS
$-1.58
Book Value
$3.39
P/E Ratio
-11.4x
Price/Sales (TTM)
3.5
Price/Cash Flow (TTM)
---
Operating Margin
-33.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.